NCT00560638View on ClinicalTrials.gov

Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye

PHASE2CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions
Dry Eye
Interventions
DRUG

loteprednol etabonate ophthalmic suspension, 0.5%

TID

DRUG

loteprednol etabonate ophthalmic suspension, 0.5%

QID

DRUG

vehicle of loteprednol etabonate

TID or BID according to the randomization

Trial Locations (1)

01810

Ophthalmic Research Associates, Andover

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT00560638 - Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye | Biotech Hunter | Biotech Hunter